A Phase 3 interventional study of Alirocumab and Placebo (for Alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-27.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 26th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 14th largest by enrollment, is one of 5 that started in 2013, is one of 22 in phase 3, and was the 25th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background therapy or as monotherapy in comparison with placebo in participants with primary hypercholesterolemia not treated with a statin.
Secondary Objective:
Alirocumab 75 mg Q2W was added as a calibrator arm.
The core study duration was approximately 35 weeks per participant (screening: 3 weeks, double-blind treatment period: 24 weeks; follow-up: 8 weeks). Participants who successfully completed the treatment period had the possibility to participate in an optional open-label treatment period with Alirocumab 150 mg Q4W until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with primary hypercholesterolemia (heterozygous familial hypercholesterolemia [heFH] or non-FH) not adequately controlled with their non-statin LMT (either ezetimibe or fenofibrate) or diet alone.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks. Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed.
Drug: Alirocumab · Drug: Placebo (for Alirocumab) · Drug: Non-statin LMT · Other: Diet Alone
Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline. Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed.
Drug: Alirocumab · Drug: Non-statin LMT · Other: Diet Alone
Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline. Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed.
Drug: Alirocumab · Drug: Placebo (for Alirocumab) · Drug: Non-statin LMT · Other: Diet Alone
Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Also known as: SAR236553, REGN727, Praluent®
Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Ezetimibe or Fenofibrate at stable dose as background therapy.
Stable cholesterol-lowering diet as background therapy.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis
Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and \<5%. High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia. Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion \>50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included.
Time frame: From Baseline to Week 24
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis
Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 32, 36, 48, 72, 96, 120, 144, 168 On-Treatment Analysis in Open Label Extension Treatment Phase
Mean percent changes (and standard deviations) observed during the open-label extension period are provided.
Time frame: Baseline, Week 32, 36, 48, 72, 96, 120, 144 and Week 168
The study was conducted at 43 centers in 8 countries. A total of 402 participants were screened between December-2013 and May-2014, of whom 233 were randomized for double-blind (DB) treatment period and 169 were screen failures. Out of 233 randomized for DB period, 205 participants entered the optional open-label (OL) extension period.
| Milestone | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Started | 58 | 116 | 59 |
| Treated | 58 | 115 | 58 |
| Completed | 54 | 107 | 50 |
| Not completed | 4 | 9 | 9 |
| Withdrew: Adverse event | 2 | 2 | 5 |
| Withdrew: Poor compliance to protocol | 0 | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Consent withdrawn by participant | 1 | 0 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 | 1 |
| Withdrew: Other than specified above | 1 | 3 | 1 |
| Milestone | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Started | 51 | 106 | 48 |
| Completed | 46 | 89 | 43 |
| Not completed | 5 | 17 | 5 |
| Withdrew: Adverse event | 1 | 7 | 3 |
| Withdrew: Poor compliance to protocol | 1 | 1 | 0 |
| Withdrew: Participant moved | 1 | 2 | 0 |
| Withdrew: Other than specified above | 2 | 7 | 2 |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) | 4.7 ± 2.3 | -53.5 ± 1.6 | -51.7 ± 2.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | 5.1 ± 2.1 | -55.3 ± 1.5 | -54.6 ± 2.1 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | 3.2 ± 2.5 | -50.8 ± 1.7 | -41.7 ± 2.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | 3.6 ± 2.3 | -51.5 ± 1.6 | -44.8 ± 2.3 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis | 3.2 ± 2.0 | -53.6 ± 1.4 | -52.3 ± 2.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis | 3.6 ± 1.9 | -54.1 ± 1.3 | -55.0 ± 1.9 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | 7.5 ± 2.1 | -39.7 ± 1.5 | -38.9 ± 2.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis | 7.7 ± 2.0 | -41.2 ± 1.4 | -40.9 ± 2.1 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis | 4.8 ± 2.1 | -45.3 ± 1.5 | -44.2 ± 2.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis | 5.0 ± 1.9 | -46.9 ± 1.3 | -46.7 ± 1.9 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 24 - ITT Analysis | 3.0 ± 1.6 | -34.0 ± 1.1 | -32.3 ± 1.6 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | 7.0 ± 2.2 | -38.4 ± 1.6 | -31.3 ± 2.2 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | 3.0 ± 2.2 | -43.4 ± 1.5 | -34.9 ± 2.2 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | 1.8 ± 1.6 | -32.6 ± 1.2 | -24.5 ± 1.6 |
Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and \<5%. High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia. Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion \>50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included.
| percentage of participants | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis | 1.8 | 70.3 | 63.9 |
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percentage of participants | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis | 1.8 | 72.7 | 67.7 |
Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percentage of participants | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis | 0.0 | 60.0 | 50.0 |
Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percentage of participants | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis | 0.0 | 61.7 | 50.9 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | 4.1 ± 3.7 | -21.8 ± 2.6 | -15.5 ± 3.7 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | 2.2 ± 3.4 | -16.5 ± 2.4 | -5.7 ± 3.3 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | -2.4 ± 1.9 | 7.4 ± 1.4 | 7.7 ± 2.0 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | -0.8 ± 1.9 | 6.8 ± 1.3 | 8.6 ± 1.9 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | 1.1 ± 3.8 | -10.6 ± 2.7 | -9.2 ± 3.9 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | 2.1 ± 3.9 | -11.3 ± 2.7 | -3.0 ± 3.8 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | 3.4 ± 1.5 | 8.2 ± 1.1 | 10.0 ± 1.5 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Alirocumab 150 mg Q4W/Up to 150 mg Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | 2.6 ± 1.5 | 5.9 ± 1.1 | 7.6 ± 1.5 |
Mean percent changes (and standard deviations) observed during the open-label extension period are provided.
| percent change | Alirocumab 150 mg Q4W (After Placebo Q2W) | Alirocumab 150 mg QW4 (After Alirocumab 75 Q2W/Up 150 Q2W) | Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up 150 Q2W) |
|---|---|---|---|
| Week 32 | -37.3 ± 18.8 | -41.1 ± 21.2 | -46.9 ± 13.3 |
| Week 36 | -36.1 ± 22.0 | -39.2 ± 21.2 | -43.1 ± 13.7 |
| Week 48 | -46.5 ± 24.2 | -49.2 ± 18.7 | -48.7 ± 21.7 |
| Week 72 | -50.8 ± 20.6 | -53.7 ± 19.5 | -52.3 ± 21.3 |
| Week 96 | -49.8 ± 20.4 | -52.8 ± 19.6 | -46.8 ± 22.0 |
| Week 120 | -50.6 ± 20.9 | -53.7 ± 18.7 | -51.8 ± 24.1 |
| Week 144 | -52.7 ± 17.6 | -48.7 ± 23.7 | -49.4 ± 20.9 |
| Week 168 | -47.8 ± 24.2 | -66.2 ± 17.1 | -60.0 ± 4.6 |
Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion (up to 176 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | 0/58 (0%) | 4/58 (6.9%) | 28/58 (48.3%) |
| Alirocumab 75 mg Q2W/Up150 mg Q2W | 0/115 (0%) | 7/115 (6.1%) | 61/115 (53%) |
| Alirocumab 150 mg Q4W/Up150 mg Q2W | 0/58 (0%) | 7/58 (12.1%) | 29/58 (50%) |
| Alirocumab 150 mg Q4W (After Placebo Q2W) | 0/51 (0%) | 15/51 (29.4%) | 42/51 (82.4%) |
| Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W) | 2/106 (1.9%) | 28/106 (26.4%) | 71/106 (67%) |
| Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W) | 1/48 (2.1%) | 14/48 (29.2%) | 31/48 (64.6%) |
| Event | Placebo Q2W | Alirocumab 75 mg Q2W/Up150 mg Q2W | Alirocumab 150 mg Q4W/Up150 mg Q2W | Alirocumab 150 mg Q4W (After Placebo Q2W) | Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W) | Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W) |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/58 | 1/115 | 0/58 | 1/51 | 1/106 | 2/48 |
| SyncopeNervous system disorders | 0/58 | 0/115 | 0/58 | 0/51 | 3/106 | 2/48 |
| FallInjury, poisoning and procedural complications | 1/58 | 0/115 | 0/58 | 2/51 | 1/106 | 0/48 |
| Acute myocardial infarctionCardiac disorders | 0/58 | 0/115 | 1/58 | 0/51 | 3/106 | 0/48 |
| Atrial fibrillationCardiac disorders | 0/58 | 0/115 | 0/58 | 1/51 | 0/106 | 1/48 |
| Cardio-respiratory arrestCardiac disorders | 0/58 | 0/115 | 0/58 | 0/51 | 0/106 | 1/48 |
| Coronary artery diseaseCardiac disorders | 0/58 | 0/115 | 0/58 | 0/51 | 2/106 | 1/48 |
| FaecalomaGastrointestinal disorders | 0/58 | 0/115 | 0/58 | 0/51 | 0/106 | 1/48 |
| Small intestinal obstructionGastrointestinal disorders | 0/58 | 0/115 | 0/58 | 0/51 | 1/106 | 1/48 |
| CellulitisInfections and infestations | 0/58 | 0/115 | 0/58 | 0/51 | 0/106 | 1/48 |
| Event | Placebo Q2W | Alirocumab 75 mg Q2W/Up150 mg Q2W | Alirocumab 150 mg Q4W/Up150 mg Q2W | Alirocumab 150 mg Q4W (After Placebo Q2W) | Alirocumab 150 mg Q4W (After Alirocumab 75 Q2W/Up150 Q2W) | Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up150 Q2W) |
|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 3/58 | 10/115 | 5/58 | 5/51 | 16/106 | 9/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/58 | 3/115 | 1/58 | 9/51 | 9/106 | 1/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/58 | 8/115 | 7/58 | 8/51 | 7/106 | 3/48 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/58 | 0/115 | 0/58 | 8/51 | 7/106 | 3/48 |
| Injection site reactionGeneral disorders | 0/58 | 4/115 | 8/58 | 1/51 | 7/106 | 7/48 |
| Back painMusculoskeletal and connective tissue disorders | 0/58 | 5/115 | 2/58 | 4/51 | 10/106 | 7/48 |
| Upper respiratory tract infectionInfections and infestations | 4/58 | 4/115 | 3/58 | 7/51 | 8/106 | 4/48 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/58 | 7/115 | 3/58 | 7/51 | 6/106 | 1/48 |
| FallInjury, poisoning and procedural complications | 1/58 | 6/115 | 0/58 | 6/51 | 14/106 | 2/48 |
| Non-cardiac chest painGeneral disorders | 3/58 | 3/115 | 0/58 | 6/51 | 5/106 | 1/48 |
| Age, Continuous(years) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 63.1 ± 10.7 | 62.5 ± 9.9 | 64.2 ± 10.0 | 63.1 ± 10.1 |
| Sex: Female, Male(Participants) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| Female | 27 | 47 | 29 | 103 |
| Male | 31 | 69 | 30 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 7 | 4 | 12 |
| Not Hispanic or Latino | 57 | 109 | 54 | 220 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 4 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 3 | 1 | 5 |
| White | 56 | 108 | 55 | 219 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 158.5 ± 47.3 | 154.5 ± 44.6 | 163.9 ± 69.1 | 157.9 ± 52.4 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo Q2W | Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | Alirocumab 150 mg Q4W/Up to 150 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 4.106 ± 1.226 | 4.002 ± 1.154 | 4.245 ± 1.789 | 4.089 ± 1.356 |
The record gives a start of Dec 2013, a primary completion of Oct 2014 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 4 months after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab